Successful treatment of COVID-19 with remdesivir in the absence of humoral immunity
暂无分享,去创建一个
William L. Hamilton | N. Loman | J. Quick | W. Ouwehand | R. Döffinger | P. Klenerman | S. Bloor | P. Lehner | I. Wilkinson | A. Smielewska | P. Lyons | J. Stockton | L. Estcourt | A. Yakovleva | N. Provine | E. Toonen | D. Roberts | I. Goodfellow | L. Bergamaschi | J. Galloway | J. Thaventhiran | J. Periselneris | S. Grigoriadou | P. Morgan | E. Torok | L. Devlin | S. Lear | M. Hunter | S. Kiani-Alikhan | N. Screaton | M. Buckland | L. Turner | James E. D. Thaventhiran | J. Bradley | L. Meredith | A. Ogbe | Carl-Philipp Hackstein | W. Zelek | L. Ceron-Gutierrez | D. Vaghela | V. Vieira | Ken G. C. Smith | F. Mescia | T. Coulter | N. Matheson | Peter Nelson | Caoimhe Nic Fhogartaig | Tiffeney Mann | H. D. Akther | Heli Harvala Simmonds | Joanne Stockton | T. Mann | J. Bradley | Nicholas J Matheson
[1] Lee-Jen Wei,et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. , 2020, The New England journal of medicine.
[2] J. Greenbaum,et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.
[3] Yi Wang,et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial , 2020, The Lancet.
[4] M. Tay,et al. The trinity of COVID-19: immunity, inflammation and intervention , 2020, Nature Reviews Immunology.
[5] V. Lougaris,et al. A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia , 2020, Journal of Allergy and Clinical Immunology.
[6] M. Chiarini,et al. Two X‐linked agammaglobulinemia patients develop pneumonia as COVID‐19 manifestation but recover , 2020, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.
[7] Joy Y. Feng,et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency , 2020, The Journal of Biological Chemistry.
[8] Erwan L'Her,et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19 , 2020, The New England journal of medicine.
[9] Huanhuan Gao,et al. Proteomic and Metabolomic Characterization of COVID-19 Patient Sera , 2020, Cell.
[10] Xuhui Huang,et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro , 2020, Antiviral Research.
[11] Lei Liu,et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 , 2020, medRxiv.
[12] Yan Zhao,et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.
[13] Wu Zhong,et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.
[14] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[15] Chuan Qin,et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. , 2019, JCI insight.
[16] Lisa E. Gralinski,et al. Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis , 2018, mBio.
[17] P. T. Ten Eyck,et al. Recovery from the Middle East respiratory syndrome is associated with antibody and T cell responses , 2017, Science Immunology.
[18] K. Sullivan,et al. Enteroviruses in X-Linked Agammaglobulinemia: Update on Epidemiology and Therapy. , 2016, The journal of allergy and clinical immunology. In practice.
[19] O. Pybus,et al. B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection , 2010, Nature communications.
[20] K. Fink,et al. Impaired Antibody Response Causes Persistence of Prototypic T Cell–Contained Virus , 2009, PLoS biology.
[21] David A. Price,et al. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover , 2007, The Journal of experimental medicine.
[22] S. Frost,et al. Hepatitis C virus and alanine aminotransferase kinetics following B-lymphocyte depletion with rituximab: evidence for a significant role of humoral immunity in the control of viremia in chronic HCV liver disease. , 2007, Blood.
[23] D. Ho,et al. Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals , 2005, Journal of medical virology.
[24] P. Klenerman,et al. Additive Effect of Neutralizing Antibody and Antiviral Drug Treatment in Preventing Virus Escape and Persistence , 2000, Journal of Virology.
[25] J. Galama,et al. Antibodies against enteroviruses in intravenous Ig preparations: Great variation in titres and poor correlation with the incidence of circulating serotypes , 1997, Journal of medical virology.